. 2022 Jun 5;14(6):e25665. doi: 10.7759/cureus.25665

Table 4. Association between the type of immunotherapy and pneumonitis grade.

(a) PD-1: programmed cell death-1; (b) PD-L1: programmed death-ligand 1; (c) both “3. Anti-Cytotoxic T-Lymphocyte Associated Protein-4 (CTLA-4): Ipilimumab and Atezolizumab”, and “7. Anti-cluster of differentiation 20 (CD20): Rituximab” are not shown because each had no patients; (d) EGFR: epidermal growth factor receptor; (e) VEGF: vascular endothelial growth factor. (f) RANKL: Receptor Activator of Nuclear Factor-kappa B

	Statistics	Grade 1	Grade 2	Grade 3	Grades 4 or 5	Total
1. Anti-PD1 ^(a) (Nivolumab and Pembrolizumab)	Count	14	22	44	9	89
1. Anti-PD1 ^(a) (Nivolumab and Pembrolizumab)	% Within Treatment Type	15.7%	24.7%	49.4%	10.1%	100.0%
2. Anti-PDL1 ^(b) (Durvalumab and Atezolizumab)	Count	14	15	17	5	51
2. Anti-PDL1 ^(b) (Durvalumab and Atezolizumab)	% Within Treatment Type	27.5%	29.4%	33.3%	9.8%	100.0%
4^(c). Anti-EGFR ^(d)(Cetuximab)	Count	0	0	1	0	1
4^(c). Anti-EGFR ^(d)(Cetuximab)	% Within Treatment Type	0.0%	0.0%	100.0%	0.0%	100.0%
5. Anti-VEGF ^(e)(Bevacizumab and Ramucirumab)	Count	1	1	1	0	3
5. Anti-VEGF ^(e)(Bevacizumab and Ramucirumab)	% Within Treatment Type	33.3%	33.3%	33.3%	0.0%	100.0%
6. Anti-RANKL ^(f) (Denosumab)	Count	0	1	0	0	1
6. Anti-RANKL ^(f) (Denosumab)	% Within Treatment Type	0.0%	100.0%	0.0%	0.0%	100.0%
Total	Count	29	39	63	14	145
Total	% Within Treatment Type	20.0%	26.9%	43.4%	9.7%	100.0%